PFD report

Miss Hannah Enola Angela Ayomipo Jacobs · Prevention of Future Deaths report

Pin Get email alerts Request correction

Issued 20 Aug 2024•East London

Report record

Published report and response evidence

This page connects the concerns raised in this report with statements found in recipients’ published responses. A link shows a clear evidence connection; it does not assign responsibility.

View original report
Concerns
2

Raised in this report

Recipients
2

Named on the report

Responses found
1

Of 2 recipients

Stated actions
4

Described in responses

Source document

Full report text

This is the full text from the original published report.

Open published report

Concerns and recipient responses

Select any concern, action or position to view the source wording.

Report evidence summary

Concerns raised2

  1. Absence of an appropriate structure to educate schools, patients and parents about carrying adrenaline autoinjectors during journeys to and from school
    Part of recurring concern: Inadequate anaphylaxis safety education for patients, parents and schools
  2. Lack of arrangements to contain the risk of anaphylaxis during journeys to and from school
Responses linked to these concerns

Each statement is shown once, even when linked to more than one concern.

Actions described in response An action is something a recipient says it has done, is doing, or plans to do in response to a concern raised.2

  1. Action

    Publish guidance enabling schools to obtain and use spare adrenaline auto-injectors in emergencies, including advice on carrying two devices and access during travel.

    Stated by Department for EducationStated completedThe respondent said that this action was complete when they made their response on 30 August 2024.
  2. Action

    Maintain guidance on school use of adrenaline auto-injectors under review, including access during travel to and from school.

    Stated by Department for EducationStated in progressThe respondent said that this action was in progress when they made their response on 30 August 2024.

Respondent positions A position is what a recipient says about a concern when it does not describe a specific action.2

  1. Position

    Current MHRA guidance is considered sufficient to address advice on carrying two adrenaline autoinjectors and using them promptly; no revision is planned.

    Stated by Department for EducationExisting arrangements considered sufficientThe respondent said that existing arrangements were sufficient, so no further action was needed.

Source evidence

How this individual concern was interpreted

PFD Monitor created a concise, searchable interpretation from the report wording shown below. Response links show a clear evidence connection; they do not assign responsibility.

PFD Monitor interpretation

Absence of an appropriate structure to educate schools, patients and parents about carrying adrenaline autoinjectors during journeys to and from school

Wider context from the report

“• Hannah was regularly prescribed Epi-pens (AAI) and had 2 at home and 2 at school. There was no consideration about how to contain the risk of anaphylaxis on the journey to and from school. • Her paediatrician gave evidence at the inquest and acknowledged it was a difficult issue as the pens can be misused, lost, forgotten, leaving an absence of pens at home at the weekend. However, the largest cause of mortality in anaphylaxis is the absence of a readily available adrenaline autoinjector. • The risk of future deaths in the context of anaphylaxis remain in the absence of an appropriate structure to educate the school, patients and the parents of the importance of carrying an AAI on their way to and from school. ”

Is this part of a recurring concern?

Yes — Inadequate anaphylaxis safety education for patients, parents and schools.

Open source report

Source evidence

How this individual concern was interpreted

PFD Monitor created a concise, searchable interpretation from the report wording shown below. Response links show a clear evidence connection; they do not assign responsibility.

PFD Monitor interpretation

Lack of arrangements to contain the risk of anaphylaxis during journeys to and from school

Wider context from the report

“• Hannah was regularly prescribed Epi-pens (AAI) and had 2 at home and 2 at school. There was no consideration about how to contain the risk of anaphylaxis on the journey to and from school. • Her paediatrician gave evidence at the inquest and acknowledged it was a difficult issue as the pens can be misused, lost, forgotten, leaving an absence of pens at home at the weekend. However, the largest cause of mortality in anaphylaxis is the absence of a readily available adrenaline autoinjector. • The risk of future deaths in the context of anaphylaxis remain in the absence of an appropriate structure to educate the school, patients and the parents of the importance of carrying an AAI on their way to and from school. ”

Is this part of a recurring concern?

No recurring-concern membership is currently published.

Open source report

Source evidence

How this respondent action was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

Publish guidance enabling schools to obtain and use spare adrenaline auto-injectors in emergencies, including advice on carrying two devices and access during travel.

Verbatim wording from the response

“In 2017, the Department of Health published non-statutory guidance to accompany a legislative change to allow schools to purchase spare AAIs from a pharmacy, without a prescription and for use in an emergency situation. This guidance gives clear advice to schools on the recognition and management of an allergic reaction and anaphylaxis, and outlines when and how an AAI should be administered for pupils in schools. The guidance states that children at risk of anaphylaxis should have their prescribed AAIs at school for use in an emergency, and in line with MHRA advice, those prescribed AAIs should carry two devices at all times. The guidance also states that depending on their level of understanding and competence, children and particularly teenagers should carry their AAIs on their person at all times or they should be quickly and easily accessible at all times.”

Source location

Joint response from DHSC & DfE
Page 3 · response
Published 30 August 2024

Open published response

Source evidence

How this respondent action was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

Maintain guidance on school use of adrenaline auto-injectors under review, including access during travel to and from school.

Verbatim wording from the response

“forgets to bring the AAIs to school each day. Where this occurs, the guidance states that the pupil must still have access to an AAI when travelling to and from school.”

Source location

Joint response from DHSC & DfE
Page 4 · response
Published 30 August 2024

Open published response

Source evidence

How this respondent position was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

Current MHRA guidance is considered sufficient to address advice on carrying two adrenaline autoinjectors and using them promptly; no revision is planned.

Verbatim wording from the response

“In June 2023, the MHRA launched new guidance to highlight the latest safety advice from the Commission on Human Medicines (CHM)’s working group on the safe and effective use of AAIs. The guidance included advice for healthcare professionals to provide to patients and carers and reinforces the importance of carrying 2 AAIs at all times, and using AAIs without delay if anaphylaxis is suspected, even if in doubt about the severity of the event. The guidance can be accessed at the following link: https://www.gov.uk/government/publications/adrenaline-auto-injectors-aais-safety-campaign/adrenaline-auto-injectors-aais”

Source location

Joint response from DHSC & DfE
Page 2 · response
Published 30 August 2024

Open published response

Source evidence

How this respondent position was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

Existing school duties and guidance are considered sufficient to require allergy arrangements and access to adrenaline autoinjectors during travel to and from school.

Verbatim wording from the response

“Section 100 of the Children and Families Act 2014 places a legal duty on schools to make arrangements for supporting pupils at their school with medical conditions. The accompanying statutory guidance - Supporting Pupils at School with Medical Conditions - is not voluntary; schools are legally required to have regard to this guidance when carrying out their section 100 duty.”

Source location

Joint response from DHSC & DfE
Page 3 · response
Published 30 August 2024

Open published response

Other statements in published responses

These actions and other statements could not be clearly connected to one concern in this report.

Recipient-stated actions An action is something a recipient says it has done, is doing, or plans to do in response to a concern raised.2

  1. 1

    Work with AAI suppliers and supply-chain partners to prevent shortages and minimise patient risks when shortages arise.

    Stated by Department for EducationStated in progressThe respondent said that this action was in progress when they made their response on 30 August 2024.
  2. 2

    Operate the Expert Advisory Group for Allergy to identify allergy policy priorities and advise on improved support and outcomes.

    Stated by Department for EducationStated completedThe respondent said that this action was complete when they made their response on 30 August 2024.

Source evidence

How this respondent action was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

Work with AAI suppliers and supply-chain partners to prevent shortages and minimise patient risks when shortages arise.

Verbatim wording from the response

“In relation to shortages of AAIs, DHSC works closely with all suppliers of AAIs to ensure supplies remain available for patients. We understand that in February 2023 all suppliers of adrenaline 0.3mcg auto-injectors were in stock, including EpiPen. One supplier of 0.15mcg had been out of stock since early 2020 but the remaining two suppliers, including EpiPen, were available in sufficient quantities to support patient demand. The sole supplier of the 0.5mcg pen (Emerade) was also in stock during this time.”

Source location

Joint response from DHSC & DfE
Page 4 · response
Published 30 August 2024

Open published response

Source evidence

How this respondent action was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

Operate the Expert Advisory Group for Allergy to identify allergy policy priorities and advise on improved support and outcomes.

Verbatim wording from the response

“An Expert Advisory Group for Allergy (EAGA) has been established, which brings together key stakeholders with the aim improving the quality-of-life of people with allergies. Chaired jointly by DHSC and the National Allergy Strategy Group, EAGA identifies priority areas for DHSC, NHS England and other government departments and agencies relating to allergy that require policy change or development and advises on how best to achieve improved outcomes and improve support for people with allergies.”

Source location

Joint response from DHSC & DfE
Page 4 · response
Published 30 August 2024

Open published response
Back to top

Information checked against the published report and official responses · Data reviewed 7 Sep 2026 · About data quality and limitations

Official responses located
1/2

Data last updated 7 September 2026